MAP Pharmaceuticals, Inc.

Form 4

March 11, 2010

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

**OMB APPROVAL** 

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Bay City Capital Fund IV, L.P.

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

(First)

(Street)

(State)

(Middle)

(Zip)

MAP Pharmaceuticals, Inc. [MAPP] 3. Date of Earliest Transaction

(Check all applicable)

C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET,

SUITE 400

(City)

(Last)

(Month/Day/Year)

03/09/2010

Director X 10% Owner \_ Other (specify Officer (give title below)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

SAN FRANCISCO, CA 94111

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) nsaction Disposed of (D) de (Instr. 3, 4 and 5) str. 8)  (A) or de V Amount (D) Price			5. Amount of Securities Ownership Beneficially Form: Owned Direct (D) Following or Indirect Reported (I) Transaction(s) (Instr. 4) (Instr. 3 and 4)	
Common Stock	03/09/2010		S	151,424	` ´		2,195,653	I	See Footnote (1)
Common Stock	03/10/2010		S	134,190	D	\$ 16.03	2,061,463	I	See Footnote (2)
Common Stock	03/11/2010		S	54,300	D	\$ 16.06	2,007,163	I	See Footnote (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: MAP Pharmaceuticals, Inc. - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title	and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	onNumber	Expiration D	ate	Amoun	it of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underly	ying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securit	ies	(Instr. 5)	Bene
	Derivative				Securities			(Instr. 3	3 and 4)		Own
	Security				Acquired						Follo
	·				(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						Ì
					4, and 5)						
								1	Amount		
						Date	Expiration		or		
						Exercisable	Date	Title Number			
									of		
				Code V	(A) (D)				Shares		

## **Reporting Owners**

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

Bay City Capital Fund IV, L.P. C/O BAY CITY CAPITAL LLC 750 BATTERY STREET, SUITE 400 SAN FRANCISCO, CA 94111

X

### **Signatures**

/s/ Carl 03/11/2010 Goldfisher

\*\*Signature of Date Reporting Person

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Includes 46,325 shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Fund IV"), an affiliate of Bay City Capital (1) Fund IV, L.P., which disclaims beneficial ownership of the shares held by Bay City Capital Fund IV Co-Investment Fund, L.P., except to the extent of its pecuniary interest therein.
- Includes 43,494 shares held by Co-Fund IV, an affiliate of Bay City Capital Fund IV, L.P., which disclaims beneficial ownership of the **(2)** shares held by Co-Fund IV, except to the extent of its pecuniary interest therein.
- Includes 42,348 shares held by Co-Fund IV, an affiliate of Bay City Capital Fund IV, L.P., which disclaims beneficial ownership of the **(3)** shares held by Co-Fund IV, except to the extent of its pecuniary interest therein.

Reporting Owners 2

### Edgar Filing: MAP Pharmaceuticals, Inc. - Form 4

#### **Remarks:**

Signed by Carl Goldfischer, Managing Director of Bay City Capital LLC, for and on behalf of Bay City Capital Fund IV, L.P.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.